Imagine a continent where a deadly disease like cholera could be prevented with a locally-made vaccine, saving countless lives. That future is closer than you think, and South Africa is leading the charge.
In a groundbreaking move, South African biopharmaceutical company Biovac has received the green light from the South African Health Products Regulatory Authority (SAHPRA) to commence clinical trials for its oral cholera vaccine—a first for the country and a potential game-changer for Africa. But here's where it gets even more exciting: if successful, South Africa will become the only African nation to produce this life-saving vaccine entirely within its borders.
Health Minister Dr. Aaron Motsoaledi hailed this development as a "historic milestone", not just for Biovac and South Africa, but for the entire continent. He emphasized the significance of this achievement, stating, "Manufacturing a life-saving vaccine from start to finish here at home bolsters our ability to swiftly combat outbreaks and strengthens Africa's self-sufficiency in vaccine production. This aligns perfectly with our government's vision of ensuring health security and universal access to essential medicines."
And this is the part most people miss: This isn't just about public health. Deputy Minister of Science, Technology and Innovation, Dr. Nomalungelo Gina, highlighted the broader impact, stating that the government's commitment to local manufacturing, technology transfer, and commercialization of scientific discoveries is crucial for job creation, skills development, and industrial growth. "This benefits not only South Africa but the entire African continent," she added.
The launch of South Africa's first locally manufactured vaccine in over 50 years took place at the Chris Hani Baragwanath Academic Hospital in Soweto, Johannesburg. The event underscored the growing number of cholera outbreaks in Africa, which have been exacerbated by recurring vaccine shortages, leaving vulnerable communities at risk of preventable deaths. Cholera, though treatable with oral rehydration therapy, antibiotics, and vaccines, can be fatal during outbreaks when these interventions are unavailable.
Here's the controversial part: While the African Union (AU) has set an ambitious target for 60% of all routine vaccines used in Africa to be manufactured on the continent by 2030—a massive leap from today's less than 1%—some critics argue that this goal may be overly optimistic. What do you think? Is Africa ready to take on such a monumental task, or are there still too many hurdles to overcome? Let us know in the comments.
Biovac's vaccine development has garnered support from major global players, including the Gates Foundation, Open Philanthropy, the Wellcome Trust, and the ELMA Vaccines and Immunisation Foundation. Phase 1 of the clinical trial began in October 2025 at the University of the Witwatersrand's Perinatal HIV Research Unit (Wits' PHRU), focusing on safety testing in adults. If successful, Phase 3 will assess immunogenicity—the vaccine's ability to prevent cholera through antibody development—across five sites in Johannesburg, Durban, and East London.
Coordinated by the South African Medical Research Council (SAMRC), this trial not only showcases South Africa's capability to conduct trials for diverse products but also sets the stage for a larger Phase 3 study comparing Biovac's vaccine with Euvichol Plus, a WHO-prequalified cholera vaccine produced by EuBiologics. Depending on the trial outcomes, the vaccine could be approved for use in Africa as early as 2028 and globally by 2028/29.
Biovac CEO Dr. Morena Makhoana expressed pride in the company's achievement, stating, "If the trials succeed, South Africa will be the first African country to produce a cholera vaccine. This addresses a critical, life-saving need amid global vaccine shortages and recurring cholera outbreaks."
Biovac, established in 2003 through a government-private sector collaboration, aims to revitalize local vaccine production capabilities. Professor Glenda Gray, SAMRC Chief Scientific Officer and Distinguished Professor at Wits University, emphasized the historical significance of leading these trials, stating, "This is a vital step in strengthening our nation's ability to respond to infectious diseases. We are committed to conducting these trials with the utmost adherence to good clinical practice guidelines, ensuring the safety, care, and protection of all participants."
So, what's your take? Is South Africa's leap into local vaccine production a beacon of hope for Africa's health security, or are there challenges that could hinder this ambitious goal? Share your thoughts below—we'd love to hear from you!
